Dr Reddy’s recalls over 8,000 bottles of generic drug in US due to packaging error
时间:2024-06-26 19:06:18 阅读(143)
Dr Reddy’s Laboratories is recalling over 8,000 bottles of a generic medication used to prevent rejection of a transplanted organ from the US market due to a packaging error, according to the US Food & Drug Administration.
The Hyderabad-based drug major is recalling 8,280 bottles of Tacrolimus capsules from the US market for “presence of foreign tablets/capsules” in the affected lot.
The affected lot was produced at Dr Reddy’s Bachupally-based plant near Hyderabad.
New Jersey-based Dr Reddy’s Laboratories, Inc has initiated the nationwide (US) Class II recall on December 15, 2023.
As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Dr Reddy’s had recalled 4,000 bottles of the same drug in March last year as well. The company had initiated the recall on February 8, 2023.
上一篇:Edible oil firms cut prices as commodity costs fall
下一篇:Yoga for Humanity- PM Modi at forefront of International Day of Yoga celebrations - See photos
猜你喜欢
- Buy HDFC Bank, Divis Lab, Tech Mahindra others, charts show near-term gains; Nifty forms long bullish candle
- Sensex zooms past 60000; Nifty ends near 17950, next target seen at 18175, here’s what analysts say
- European shares drop as rate hike jitters weigh; Embracer slips
- Sensex rises 130 pts, Nifty above 17950 in early trade on Monday, Feb 20; HUL stock gains, Cipla shares fall 5%
- Sensex reclaims 60k, Nifty tops 18k-mark as markets rally for 3rd day
- Sensex, Nifty open in red on Tuesday, Jan 3; HFCL shares rise over 2%, Zomato shares fall 2%
- Bihar Education Department deducted salaries of 12,987 absent teachers; suspends 39 and dismisses 13 over violations
- F&O expiry outlook September 1- If Nifty breaks 17350, long unwinding may pull index lower, caution advised
- Sensex ends flat with marginal gains, Nifty may edge higher, check support & resistance levels